Literature DB >> 30167654

Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group.

Barney J Stern1, Walter Royal2, Jeffrey M Gelfand3, David B Clifford4, Jinny Tavee5, Siddharama Pawate6, Joseph R Berger7, Allen J Aksamit8, Allan Krumholz9, Carlos A Pardo1, David R Moller10, Marc A Judson11, Marjolein Drent12, Robert P Baughman13.   

Abstract

Importance: The Neurosarcoidosis Consortium Consensus Group, an expert panel of physicians experienced in the management of patients with sarcoidosis and neurosarcoidosis, engaged in an iterative process to define neurosarcoidosis and develop a practical diagnostic approach to patients with suspected neurosarcoidosis. This panel aimed to develop a consensus clinical definition of neurosarcoidosis to enhance the clinical care of patients with suspected neurosarcoidosis and to encourage standardization of research initiatives that address this disease. Observations: The work of this collaboration included a review of the manifestations of neurosarcoidosis and the establishment of an approach to the diagnosis of this disorder. The proposed consensus diagnostic criteria, which reflect current knowledge, provide definitions for possible, probable, and definite central and peripheral nervous system sarcoidosis. The definitions emphasize the need to evaluate patients with findings suggestive of neurosarcoidosis for alternate causal factors, including infection and malignant neoplasm. Also emphasized is the need for biopsy, whenever feasible and advisable according to clinical context and affected anatomy, of nonneural tissue to document the presence of systemic sarcoidosis and support a diagnosis of probable neurosarcoidosis or of neural tissue to support a diagnosis of definite neurosarcoidosis. Conclusions and Relevance: Diverse disease presentations and lack of specificity of relevant diagnostic tests contribute to diagnostic uncertainty. This uncertainty is compounded by the absence of a pathognomonic histologic tissue examination. The diagnostic criteria we propose are designed to focus investigations on NS as accurately as possible, recognizing that multiple pathophysiologic pathways may lead to the clinical manifestations we currently term NS. Research recognizing the clinical heterogeneity of this diagnosis may open the door to identifying meaningful biologic factors that may ultimately contribute to better treatments.

Entities:  

Mesh:

Year:  2018        PMID: 30167654     DOI: 10.1001/jamaneurol.2018.2295

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  59 in total

1.  A 46-Year-Old Presenting With Inferior Mononuclear Visual Field Defect as the Sole Manifestation of Neurosarcoidosis.

Authors:  Carl Hoegerl; Addie Amper
Journal:  Cureus       Date:  2021-02-02

2.  Off Trail, On Track: an Exercise in Clinical Reasoning.

Authors:  Kreshnik Zejnullahu; Lekshmi Santhosh; Michelle Mourad; Denise M Connor
Journal:  J Gen Intern Med       Date:  2019-07-03       Impact factor: 5.128

3.  The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.

Authors:  Pietro Maggi; Martina Absinta; Pascal Sati; Gaetano Perrotta; Luca Massacesi; Bernard Dachy; Caroline Pot; Reto Meuli; Daniel S Reich; Massimo Filippi; Renaud Du Pasquier; Marie Théaudin
Journal:  Mult Scler       Date:  2019-09-19       Impact factor: 6.312

4.  Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.

Authors:  Quentin Riller; Camille Cotteret; Helga Junot; Neila Benameur; Julien Haroche; Alexis Mathian; Miguel Hie; Makoto Miyara; Patrick Tilleul; Zahir Amoura; Fleur Cohen Aubart
Journal:  J Neurol       Date:  2019-02-09       Impact factor: 4.849

5.  Neurosarcoidosis presenting as isolated VI nerve palsy.

Authors:  Chad M Kimmitt; William D M Kennedy; Golnaz Roshankar; Lindsay M Burrowes; Carlos R Camara-Lemarroy
Journal:  Neurol Sci       Date:  2020-10-23       Impact factor: 3.307

6.  Images of the month 1: Trident sign and neurosarcoidosis.

Authors:  Emily Gibbons; Daniel Whittam; Anu Jacob; Saif Huda
Journal:  Clin Med (Lond)       Date:  2021-11       Impact factor: 2.659

7.  A Neurologist's Practical Approach to Cognitive Impairment.

Authors:  Philip W Tipton; Gregory S Day; Neill Graff-Radford
Journal:  Semin Neurol       Date:  2021-11-26       Impact factor: 3.420

8.  Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis.

Authors:  Anne-Katrin Pröbstel; Xiaoyuan Zhou; Ryan Baumann; Sven Wischnewski; Michael Kutza; Olga L Rojas; Katrin Sellrie; Antje Bischof; Kicheol Kim; Akshaya Ramesh; Ravi Dandekar; Ariele L Greenfield; Ryan D Schubert; Jordan E Bisanz; Stephanie Vistnes; Khashayar Khaleghi; James Landefeld; Gina Kirkish; Friederike Liesche-Starnecker; Valeria Ramaglia; Sneha Singh; Edwina B Tran; Patrick Barba; Kelsey Zorn; Johanna Oechtering; Karin Forsberg; Lawrence R Shiow; Roland G Henry; Jennifer Graves; Bruce A C Cree; Stephen L Hauser; Jens Kuhle; Jeffrey M Gelfand; Peter M Andersen; Jürgen Schlegel; Peter J Turnbaugh; Peter H Seeberger; Jennifer L Gommerman; Michael R Wilson; Lucas Schirmer; Sergio E Baranzini
Journal:  Sci Immunol       Date:  2020-11-20

9.  Hydrocephalus as the first presenting symptom of neurosarcoidosis in two patients: a diagnosis more forthcoming in the context of systemic disease.

Authors:  Anna McKeever; Amanda Cox; Matthew Garnett; Nicholas G Cunniffe
Journal:  BMJ Case Rep       Date:  2019-08-04

10.  Multiple sclerosis and sarcoidosis: A case for coexistence.

Authors:  Charles Tyshkov; Siddharama Pawate; Michael J Bradshaw; Dorlan J Kimbrough; Tanuja Chitnis; Jeffrey M Gelfand; Lana Zhovtis Ryerson; Ilya Kister
Journal:  Neurol Clin Pract       Date:  2019-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.